Literature DB >> 11413303

Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.

U Lazdina1, T Cao, J Steinbergs, M Alheim, P Pumpens, D L Peterson, D R Milich, G Leroux-Roels, M Sällberg.   

Abstract

The nucleocapsid of the hepatitis B virus (HBV) is composed of 180 to 240 copies of the HBV core (HBc) protein. HBc antigen (HBcAg) capsids are extremely immunogenic and can activate naive B cells by cross-linking their surface receptors. The molecular basis for the interaction between HBcAg and naive B cells is not known. The functionality of this activation was evidenced in that low concentrations of HBcAg, but not the nonparticulate homologue HBV envelope antigen (HBeAg), could prime naive B cells to produce anti-HBc in vitro with splenocytes from HBcAg- and HBeAg-specific T-cell receptor transgenic mice. The frequency of these HBcAg-binding B cells was estimated by both hybridoma techniques and flow cytometry (B7-2 induction and direct HBcAg binding) to be approximately 4 to 8% of the B cells in a naive spleen. Cloning and sequence analysis of the immunoglobulin heavy- and light-chain variable (VH and VL) domains of seven primary HBcAg-binding hybridomas revealed that six (86%) were related to the murine and human VH1 germ line gene families and one was related to the murine VH3 family. By using synthetic peptides spanning three VH1 sequences, one VH3 sequence, and one VLkappaV sequence, a linear motif in the framework region 1 (FR1)complementarity-determining region 1 (CDR1) junction of the VH1 sequence was identified that bound HBcAg. Interestingly, the HBcAg-binding motif was present in the VL domain of the HBcAg-binding VH3-encoded antibody. Finally, two monoclonal antibodies containing linear HBcAg-binding motifs blocked HBcAg presentation by purified naive B cells to purified HBcAg-primed CD4(+) T cells. Thus, the ability of HBcAg to bind and activate a high frequency of naive B cells seems to be mediated through a linear motif present in the FR1-CDR1 junction of the heavy or light chain of the B-cell surface receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413303      PMCID: PMC114359          DOI: 10.1128/JVI.75.14.6367-6374.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Staphylococcal enterotoxin A induces survival of VH3-expressing human B cells by binding to the VH region with low affinity.

Authors:  R Domiati-Saad; P E Lipsky
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

2.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins.

Authors:  M Sällberg; U Rudén; L O Magnius; E Norrby; B Wahren
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

3.  Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside Triphosphatase/Helicase domain of the hepatitis C virus nonstructural 3 protein.

Authors:  Z X Zhang; U Lazdina; M Chen; D L Peterson; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.

Authors:  T Cao; U Lazdina; I Desombere; P Vanlandschoot; D R Milich; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Comparative immunogenicity of hepatitis B virus core and E antigens.

Authors:  D R Milich; A McLachlan; S Stahl; P Wingfield; G B Thornton; J L Hughes; J E Jones
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

6.  Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection.

Authors:  M Chen; M Sällberg; S N Thung; J Hughes; J Jones; D R Milich
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen.

Authors:  M Sällberg; U Rudén; L O Magnius; H P Harthus; M Noah; B Wahren
Journal:  J Med Virol       Date:  1991-04       Impact factor: 2.327

8.  Intracellular hepatitis B virus nucleocapsids survive cytotoxic T-lymphocyte-induced apoptosis.

Authors:  V Pasquetto; S Wieland; F V Chisari
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Structure of hepatitis B virus core and e-antigen. A single precore amino acid prevents nucleocapsid assembly.

Authors:  F Schödel; D Peterson; J Zheng; J E Jones; J L Hughes; D R Milich
Journal:  J Biol Chem       Date:  1993-01-15       Impact factor: 5.157

10.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.

Authors:  D R Milich; A McLachlan
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

View more
  24 in total

1.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

3.  Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids.

Authors:  Norman R Watts; Giovanni Cardone; Joe G Vethanayagam; Naiqian Cheng; Catharina Hultgren; Stephen J Stahl; Alasdair C Steven; Matti Sällberg; Paul T Wingfield
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

4.  Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.

Authors:  T Cao; U Lazdina; I Desombere; P Vanlandschoot; D R Milich; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model.

Authors:  T Cao; P Meuleman; I Desombere; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins.

Authors:  Nathalie Parez; Antoine Garbarg-Chenon; Cynthia Fourgeux; Françoise Le Deist; Annabelle Servant-Delmas; Annie Charpilienne; Jean Cohen; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus.

Authors:  Silke Arzberger; Marianna Hösel; Ulrike Protzer
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

9.  Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases.

Authors:  Cuiling Yang; Na Li; Yawen Wang; Pingping Zhang; Qianqian Zhu; Fang Li; Qunying Han; Yi Lv; Ling Yu; Ping Wei; Zhengwen Liu
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

10.  Screening and identification of interacting proteins with hepatitis B virus core protein in leukocytes and cloning of new gene C1.

Authors:  Shu-Mei Lin; Jun Cheng; Yin-Ying Lu; Shu-Lin Zhang; Qian Yang; Tian-Yan Chen; Min Liu; Lin Wang
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.